Ruxolitinib and Chidamide Intensified Bu/CY Conditioning Regimen

Recruiting now · Phase 2

Conditions studied: Peripheral Blood Stem Cell Transplantation

In brief

The purpose of this study is to determine the efficacy and safety of Ruxolitinib and Chidamide intensified conditioning regimen in patients with Acute B cell Lymphoblast leukemia Underwenting Haploidenticl Peripheral blood Stem Cell Transplantation.

Key facts

Study ID

NCT05088226

Run by

Chinese PLA General Hospital

People needed

50

Starts

2021-12-01

Expected to finish

2031-06-01

Last updated by the study team

2026-04-23

Who can join

Age: 12 and older, up to 65. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• high risk acute B cell lymphoblastic leukemia with the indications for allogeneic transplantation;
• Have matched sibling donors, ≥8/10 HLA matched unrelated donors or haploidentical donors
• All patients should aged 12 to 65 years;
• Liver function: ALT and AST≤2.5 times the upper limit of normal , bilirubin≤2 times the upper limit of normal;
• Renal function: creatinine ≤the upper limit of normal;
• Patients without any uncontrolled infections , without organ dysfunction or without severe mental illness;
• Eastern Cooperative Oncology Group (ECOG) performance status ≤2;
• Have signed informed consent.

You may not qualify if…

• pregnant women;
• Patients with mental illness or other states unable to comply with the protocol;
• ALL patients with Ph positive;

Where it is running

• Chinese PLA General Hospital — Beijing, Beijing Municipality, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.